MedTrace Logo

Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC

NCT05549778 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-07-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate clinical safety and efficacy of a gastric ulcer drug, polaprezinc (POL), with the AR-inhibitor abiraterone in Chinese patients with castration-resistant prostate cancer (CRPC).

Conditions

  • Castration-resistant Prostate Cancer

Interventions

DRUG

Polaprezinc group

Abiraterone plus Polaprezinc for 6 months

DRUG

Control group

Abiraterone, radio- or chemotherapy

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    collaborator OTHER

  • Jiangnan University

    lead OTHER

Principal Investigators

  • Yong Q Chen, MD/PHD · Jiangnan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2023-01-20
Completion
2023-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05549778 on ClinicalTrials.gov